A tale of two systems
The world of health technology is brimming with innovation, with a wave of new AI-driven platforms emerging to support both patients and doctors. However, it's crucial for UK clinicians to recognise that a digital tool built for the direct-to-consumer, insurance-based healthcare market of the United States doesn't always fit the unique structure of our National Health Service.
A new generation of impressive US healthcare AI startups, including Doctronic, CodyMD, and Docus AI, are gaining traction. While their technology is exciting, this article explores their features and business models to explain why the distinct guidelines, workflows, and principles of the NHS require a purpose-built tool.
Profiling the US players
To understand the difference, it helps to look at what these platforms are designed to do:
- Doctronic & CodyMD: Many emerging US platforms focus on a specific, commercially-driven workflow. A patient might interact with an AI chatbot which then seamlessly connects them to a paid, 24/7 video consultation with a licensed doctor. This model is perfectly tailored for the competitive US urgent care and telehealth market, where a primary goal is facilitating a billable consultation event.
- Docus AI: Other platforms like Docus AI are innovating in a different space. They offer features like AI-powered interpretation of lab tests or medical records to generate reports for a "second opinion" from a network of US and European doctors, often accessible via a direct-to-consumer subscription.
These models, alongside other international AI symptom checkers like Ubie Health, are designed to solve problems and meet demands specific to their home markets. The issue arises when we consider applying them directly to UK clinical practice.
The translation problem 1: the guidelines
UK practice draws on national and local sources: NICE, CKS and SIGN guidance, product-specific SmPCs on eMC, MHRA safety communications, specialist advice and local formularies or pathways. A general or US-oriented tool may not reflect that context, so its output must be checked rather than treated as automatically compliant.
Relying on an AI that suggests management plans based on American Academy of Family Physicians (AAFP) recommendations, or drug doses approved by the FDA but not yet by the MHRA, is a significant clinical governance and safety risk. For UK clinicians, adherence to our national guidelines is not optional; it's a fundamental part of providing safe, effective, and medico-legally sound care.
The translation problem 2: the workflow
The second major issue is the workflow. The business model of many US health AI tools is built around creating a new consultation pathway.
The reality for an NHS GP or hospital doctor is entirely different. Your primary need isn't a tool to help you facilitate a paid video call. Your need is for a tool that gives you back 30 seconds. It's the ability to instantly check a drug dose in the current UK medicines information between back-to-back appointments, or to quickly reference a specific CKS page while a patient is talking, all without disrupting the flow of a high-volume NHS clinic or ward round. NHS AI tools need to be built for speed, efficiency, and integration into the existing way of working.
Building for the NHS: the iatroX difference
This is precisely why iatroX was created. We didn't adapt a foreign model for the UK; we built a solution specifically for the problems UK clinicians face. This is the core of the iatroX vs US apps distinction.
- UK-oriented retrieval: iatroX uses retrieval-augmented generation over configured UK sources, including NICE and CKS guidance, medicines information from relevant SmPCs on eMC, and MHRA safety material. It returns citations so clinicians can inspect the source rather than relying on model memory.
- Workflow-Native: iatroX is designed for the rapid, high-volume nature of the NHS. It’s not about creating a new type of appointment; it’s about making your existing appointments safer and more efficient. It delivers precise, referenced answers in seconds so you can get on with your work.
- Free at the Point of Care: In alignment with the core principles of the NHS, iatroX is free for the end-user clinician. Our goal is to support you in your work, not to add another subscription cost to your budget.
Conclusion: think local when choosing your digital tools
The innovation coming from US startups is exciting and pushes the entire field of health technology forward. However, when it comes to tools that support clinical decision-making, one size does not fit all.
For UK clinicians, the most effective, relevant, and safest digital tools will always be those that are designed with a deep and inherent understanding of the local healthcare environment—its guidelines, its regulations, its workflows, and its principles. When choosing your AI co-pilot, it pays to think local.